Physician profile
Laura E Mcfadden
NPI 1386161800
$4,726.75
in general payments reported to CMS, 2019-2025
54 companies · $1,445 in 2025
The $1,445 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,036 · 2024: $2,245 · 2025: $1,445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,559 · Education: $168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,558.82 |
| Education | $167.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $456.70 | 2023-2025 | Calquence, Enhertu, Lynparza |
| Merck Sharp & Dohme LLC | $380.12 | 2023-2025 | Keytruda, Welireg, Lynparza |
| Novartis Pharmaceuticals Corporation | $246.57 | 2023-2025 | |
| Abbvie INC. | $230.31 | 2024-2025 | |
| Janssen Biotech, INC. | $214.86 | 2023-2025 | Rybrevant, Darzalex, Tecvayli |
| Pfizer INC. | $204.92 | 2023-2025 | |
| Celgene Corporation | $171.63 | 2023-2025 | Reblozyl, Pomalyst, Opdualag |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $162.19 | 2025 | Caplyta |
| Genzyme Corporation | $143.98 | 2023-2024 | |
| Gilead Sciences, INC. | $143.71 | 2023-2025 | Trodelvy |
| Regeneron Healthcare Solutions, INC. | $137.03 | 2023-2025 | Libtayo |
| Array Biopharma INC | $133.56 | 2023-2025 | Mektovi, Braftovi, Lorbrena |
| Eisai INC. | $131.59 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $130.94 | 2023-2025 | |
| Glaxosmithkline, LLC. | $130.66 | 2023-2025 | Ojjaara, Zejula, Jemperli |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $128.80 | 2023-2025 | Camzyos, Opdivo, Cobenfy |
| Astellas Pharma US INC | $123.75 | 2024-2025 | Veozah, Vyloy, Xospata |
| Lilly USA, LLC | $122.40 | 2023-2025 | Verzenio, Jaypirca |
| Genentech USA, INC. | $103.89 | 2023-2025 | Phesgo, Itovebi, Tecentriq |
| Takeda Pharmaceuticals U.S.A., INC. | $102.77 | 2023-2025 | Alunbrig, Fruzaqla |
| Aveo Pharmaceuticals, INC. | $94.79 | 2023-2025 | Fotivda |
| Taiho Oncology, INC. | $92.45 | 2024-2025 | |
| Tersera Therapeutics LLC | $83.80 | 2023-2024 | Zoladex, Xermelo |
| Emd Serono, INC. | $71.26 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $51.20 | 2025 | |
| Amgen INC. | $49.97 | 2023-2025 | Repatha, Otezla, Xgeva |
| Stemline Therapeutics INC. | $48.46 | 2024 | Orserdu |
| Sanofi-Aventis U.S. LLC | $41.99 | 2024 | |
| Incyte Corporation | $41.80 | 2023-2024 | Monjuvi |
| Genmab U.S., INC. | $41.59 | 2023-2024 | Tivdak |
| Daiichi Sankyo INC. | $40.40 | 2024-2025 | Enhertu |
| Ardelyx, INC. | $40.27 | 2025 | Ibsrela |
| Lundbeck LLC | $34.73 | 2025 | Rexulti |
| Exelixis INC. | $33.61 | 2024-2025 | Cabometyx |
| Rigel Pharmaceuticals, INC. | $30.01 | 2023-2024 | Rezlidhia, Tavalisse |
| Pharmacyclics LLC, An Abbvie Company | $28.13 | 2023 | Epkinly |
| Sobi, INC | $23.40 | 2024 | |
| Seagen INC. | $22.07 | 2023 | Padcev |
| Myriad Genetic Laboratories, INC. | $21.87 | 2024 | Myrisk |
| Progenics Pharmaceuticals, INC. | $21.80 | 2023 | Pylarify |
| Ipsen Biopharmaceuticals, INC | $20.46 | 2023 | Tazverik |
| Novo Nordisk INC | $17.48 | 2025 | Wegovy |
| Fresenius Kabi USA, LLC | $17.46 | 2025 | Stimufend |
| Vertex Pharmaceuticals Incorporated | $17.20 | 2025 | |
| Iovance Biotherapeutics, INC. | $16.81 | 2024 | Amtagvi |
| Servier Pharmaceuticals LLC | $16.46 | 2025 | |
| Coherus Oncology, INC. | $16.00 | 2024 | |
| Blueprint Medicines Corporation | $14.94 | 2023 | Ayvakit |
| Alexion Pharmaceuticals, INC. | $14.39 | 2024 | Ultomiris |
| Puma Biotechnology, INC. | $14.37 | 2023 | |
| Novocure INC. | $13.68 | 2025 | Optune Lua (Novottf-200t) |
| Tolmar, INC. | $13.34 | 2024 | |
| Helsinn Therapeutics (U.S.), INC. | $13.12 | 2023 | Valchlor |
| Organon LLC | $7.06 | 2025 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Mcfadden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.